Comparative analysis of diagnostic methods for the detection of Cryptococcus neoformans meningitis

Carregando...
Imagem de Miniatura
Citações na Scopus
5
Tipo de produção
article
Data de publicação
2023
Título da Revista
ISSN da Revista
Título do Volume
Editora
PUBLIC LIBRARY SCIENCE
Autores
LOMBARDI, Suzete Cleusa Ferreira Spina
SILVA, Marcos Vinicius da
CRIADO, Paulo Ricardo
ALMEIDA, Terezinha Morato Bastos de
Citação
PLOS NEGLECTED TROPICAL DISEASES, v.17, n.3, article ID e0011140, 16p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Author summaryCryptococcal meningitis is an infectious disease of global importance with high morbidity and mortality, especially among individuals with HIV/AIDS. While there have been improvements in the last two decades in the diagnosis of Cryptococcus neoformans, the methods presently employed are problematic for public hospitals in Brazil and other locations due to their extreme cost. In this study, we present a low-cost option for detection and identification of C. neoformans in noninvasive serum sample in immunosuppressed individuals, including those with HIV/AIDS. A nested PCR (5.8SrDNA-ITS) associated with the latex agglutination test has high precision in detection of suspected Cryptococcus spp. BackgroundCryptococcosis is a devastating opportunistic infection in immunocompromised individuals, primarily in people living with HIV/AIDS. This study evaluated a protocol for the early diagnosis of meningitis due to C. neoformans, utilizing established molecular techniques from serum and CSF samples. MethodsThe 18S and 5.8S (rDNA-ITS) sequence-specific nested PCR assays were compared with direct India ink staining and the latex agglutination test for detection of C. neoformans in serum and cerebrospinal fluid (CSF) from 49 Brazilian suspected meningitis patients. Results were validated with samples obtained from 10 patients negative for cryptococcosis and HIV, and by analysis of standard C. neoformans strains. Principal findingsThe 5.8S DNA-ITS PCR was more sensitive (89-100%) and specific (100%) than the 18S rDNA PCR and conventional tests (India ink staining and latex agglutination) for identification of C. neoformans. While the 18S PCR exhibited a sensitivity (72%) similar to that of the latex agglutination assay in serum samples, it was superior to the latex agglutination assay when testing CSF, with a sensitivity of 84%. However, the latex agglutination was superior to the 18SrDNA PCR in specificity in CSF (92%). The 5.8S DNA-ITS PCR yielded the highest levels of accuracy (96-100%) of any test for detection (serological and mycological) of C. neoformans in both serum and CSF. ConclusionUse of the nested 5.8S PCR was superior to other techniques for the diagnosis of cryptococcosis. The possibility of using serum, a non-invasively collected material, in a targeted 5.8S PCR analysis to identify Cryptococcus spp. is recommended, especially in immunosuppressed patients. Our results indicate that nested 5.8S PCR can increase the diagnostic capability of cryptococcosis, and we suggest its use to monitor patients in the future.
Palavras-chave
Referências
  1. Ajello L., 1963, LAB MANUAL MED MYCOL
  2. Antinori S, 2009, HIV MED, V10, P6, DOI 10.1111/j.1468-1293.2008.00645.x
  3. Aoki FH, 1999, J CLIN MICROBIOL, V37, P315, DOI 10.1128/JCM.37.2.315-320.1999
  4. BENNETT JE, 1977, AM J EPIDEMIOL, V105, P582, DOI 10.1093/oxfordjournals.aje.a112423
  5. Bialek R, 2002, CLIN DIAGN LAB IMMUN, V9, P461, DOI 10.1128/CDLI.9.2.461-469.2002
  6. Capoor M R, 2007, Indian J Med Microbiol, V25, P401
  7. Casali AK, 2003, FEMS YEAST RES, V3, P405, DOI 10.1016/S1567-1356(03)00038-2
  8. Chayakulkeeree M, 2006, INFECT DIS CLIN N AM, V20, P507, DOI 10.1016/j.idc.2006.07.001
  9. COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104
  10. Sidrim JJC, 2010, CAN J MICROBIOL, V56, P445, DOI [10.1139/w10-030, 10.1139/W10-030]
  11. Dantas KC, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-83587-1
  12. Dantas KC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190408
  13. de Oliveira RB, 2014, MYCOPATHOLOGIA, V178, P71, DOI 10.1007/s11046-014-9755-3
  14. Departamento de Doencas de Condicoes Cronicas e Infeccoes Sexualmente Transmissiveis-MINISTERIO DA SAUDE, 2017, JULHO
  15. de Aguiar PADF, 2017, REV INST MED TROP SP, V59, DOI [10.1590/S1678-9946201759013, 10.1590/s1678-9946201759013]
  16. Dyal J, 2016, MED MYCOL, V54, P361, DOI 10.1093/mmy/myv104
  17. Ellis J, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz419
  18. ERCOLANI L, 1988, J BIOL CHEM, V263, P15335
  19. Firacative C, 2018, MEM I OSWALDO CRUZ, V113, DOI 10.1590/0074-02760170554
  20. Fujita SI, 2001, J CLIN MICROBIOL, V39, P3617, DOI 10.1128/JCM.39.10.3617-3622.2001
  21. Goralska K, 2018, INFECTION, V46, P443, DOI 10.1007/s15010-018-1152-2
  22. Guo XS., 2016, NEUROIMMUNOL NEUROIN, V3, P249, DOI [10.20517/2347-8659.2016.10, DOI 10.20517/2347-8659.2016.10]
  23. Jarvis JN, 2019, CLIN INFECT DIS, V68, P393, DOI 10.1093/cid/ciy515
  24. KAUFFMAN CA, 1981, AM J CLIN PATHOL, V75, P106
  25. Kohno S, 2015, J INFECT CHEMOTHER, V21, P23, DOI 10.1016/j.jiac.2014.08.025
  26. Kuehn BM, 2020, JAMA-J AM MED ASSOC, V324, P2248, DOI 10.1001/jama.2020.22914
  27. Kwon-Chung KJ, 1992, MED MYCOL
  28. Kwon-Chung KJ, 2006, FEMS YEAST RES, V6, P574, DOI 10.1111/j.1567-1364.2006.00088.x
  29. Kwon-Chung Kyung J., 2002, Taxon, V51, P804, DOI 10.2307/1555045
  30. LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
  31. Limper AH, 2017, LANCET INFECT DIS, V17, pE334, DOI 10.1016/S1473-3099(17)30303-1
  32. Ma QL, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3744-6
  33. Martins MD, 2015, BRAZ J INFECT DIS, V19, P62, DOI 10.1016/j.bjid.2014.09.004
  34. Maziarz EK, 2016, INFECT DIS CLIN N AM, V30, P179, DOI 10.1016/j.idc.2015.10.006
  35. Mirza SA, 2003, CLIN INFECT DIS, V36, P789, DOI 10.1086/368091
  36. MITCHELL TG, 1994, J CLIN MICROBIOL, V32, P253, DOI 10.1128/JCM.32.1.253-255.1994
  37. MITCHELL TG, 1995, CLIN MICROBIOL REV, V8, P515, DOI 10.1128/CMR.8.4.515
  38. Nielsen K, 2007, EUKARYOT CELL, V6, P949, DOI 10.1128/EC.00097-07
  39. Nishikawa MM, 2003, J CLIN MICROBIOL, V41, P73, DOI 10.1128/JCM.41.1.73-77.2003
  40. Paruk HF, 2021, J NEUROL SCI, V425, DOI 10.1016/j.jns.2021.117453
  41. Perfect JR, 2010, CLIN INFECT DIS, V50, P291, DOI 10.1086/649858
  42. Prado M, 2009, MEM I OSWALDO CRUZ, V104, P513, DOI 10.1590/S0074-02762009000300019
  43. Rajasingham R, 2022, LANCET INFECT DIS, V22, P1748, DOI 10.1016/S1473-3099(22)00499-6
  44. Rajasingham R, 2019, J CLIN MICROBIOL, V57, DOI 10.1128/JCM.01238-18
  45. Rajasingham R, 2017, LANCET INFECT DIS, V17, P873, DOI [10.1016/s1473-3099(17)30243-8, 10.1016/S1473-3099(17)30243-8]
  46. Rappelli P, 1998, J CLIN MICROBIOL, V36, P3438, DOI 10.1128/JCM.36.11.3438-3440.1998
  47. Riha RL., 2018, BMJ-BRIT MED J
  48. Saha DC, 2009, J MED MICROBIOL, V58, P1098, DOI 10.1099/jmm.0.007328-0
  49. Schub T, 2021, CURR MICROBIOL, V78, P3989, DOI 10.1007/s00284-021-02664-w
  50. Severo CB, 2009, J BRAS PNEUMOL, V35, P1136, DOI 10.1590/S1806-37132009001100012
  51. Soares EA, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007569
  52. Tadeo KK, 2021, J CLIN MICROBIOL, V59, DOI 10.1128/JCM.00860-21
  53. Takahashi T, 2003, J INT MED RES, V31, P324, DOI 10.1177/147323000303100411
  54. UNAIDS, 2022, GLOB AIDS MON
  55. Vianna CMM., 2021, REV I MED TROP SAO P, V63, pe57, DOI [10.1590/S1678-9946202163057, DOI 10.1590/S1678-9946202163057, 10.1590/s1678-9946202163057]
  56. Vidal JE, 2018, REV INST MED TROP SP, V60, DOI [10.1590/S1678-9946201860001, 10.1590/s1678-9946201860001]
  57. Vidal JE, 2015, REV INST MED TROP SP, V57, P38, DOI 10.1590/S0036-46652015000700008
  58. Wagner EH, 1996, EPIDEMIOLOGIA CLIN E
  59. Wirth F, 2018, BRAZ J INFECT DIS, V22, P495, DOI 10.1016/j.bjid.2018.11.002